Metastatic Pancreatic Cancer With George P. Kim, MD, and Eileen M. O'Reilly, MD: Case 2 - Episode 12
How has the availability of effective therapies shifted the treatment paradigm for patients with pancreatic cancer?
We have a frontline option, we have a second-line option, and for some patients we have a third-line option in terms of standard choices. I think we are considering more and more what’s available as the backup option in terms of how we select our frontline choice. Our sense is that all of the treatment that’s delivered contributes to the best outcome and we know that in colon cancer, for example, that giving all the active drugs5-FU, oxaliplatin, irinotecan, the biologics—that having access to those for an individual patient maximizes the chances of the best outcome. We don’t have black and white data yet that would support that statement in pancreas cancer but I think it’s coming as we integrate more and more second-line therapies and, increasingly, our discussion on third-line therapy for patients.
Metastatic Pancreatic Cancer: Case 2
Henry R was diagnosed with adenocarcinoma in the body of the pancreas when he was 64 years old, following rapid weight loss, abdominal pains, and the development of venous thrombosis.
Upfront treatment was administered with nab-paclitaxel and gemcitabine, which lasted for 4months: